"CRd is highly active in NDMM, providing rapid and deep responses. Extended treatment was well tolerated and resulted in improved depth of response with a high sCR rate and a significant proportion of pts without evidence of MRD. Responses were durable with very promising PFS. All pts who achieved sCR remained on CRd with sustained sCR. These results compare favorably to other frontline regimens."
NDMM=newly diagnosed multiple myeloma pts
http://abstract.asco.org/AbstView_114_100344.html
Forums
10 posts
• Page 1 of 1
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
It's interesting that the extract did not report the response rates by risk categories. The high response numbers seem to indicate the combination is effective despite the patients' risks. It would be great if it is true. Look forward to seeing the paper in its entirety.
-
Ben S.
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Hi Ben.
I too am anxiously awaiting the complete text vs abstract to see risk stratification outcomes.
Also I believe Jakobuwiak is making an oral presentation the morning the conference opens and hopefully he will have slides and likely mention the risk outcomes then.
Word on the street is that patients with Tp53 patients did well in this trial.
That would be very exciting news!!
I too am anxiously awaiting the complete text vs abstract to see risk stratification outcomes.
Also I believe Jakobuwiak is making an oral presentation the morning the conference opens and hopefully he will have slides and likely mention the risk outcomes then.
Word on the street is that patients with Tp53 patients did well in this trial.
That would be very exciting news!!
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
I just Made an appointment to see Dr. J here in Chgo (June 25th). I am anxious to see what he has to say about my SMM. I am hoping we will hit it off and I can keep him as my Local multiple myeloma Dr. I know he is more open minded when it comes to upfront SCT's.
My current Dr. Is very adamant about me having an upfront SCT if and when I progress. I am not sure if that is for me! I like him very much otherwise. I wish there would be an open CRD trial at UofC. They show one listed but it appears it's closed or not currently recruiting. I guess I will find out soon enough.
Best wishes to all
Art
My current Dr. Is very adamant about me having an upfront SCT if and when I progress. I am not sure if that is for me! I like him very much otherwise. I wish there would be an open CRD trial at UofC. They show one listed but it appears it's closed or not currently recruiting. I guess I will find out soon enough.
Best wishes to all
Art
-
Art - Name: Art
- Who do you know with myeloma?: Self
- When were you/they diagnosed?: 12/2011
- Age at diagnosis: 40
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Hi ART!!
I think you will be pleased with Jakubowiak...he is a good buddy of Langren.so I think that bodes well.
I hear you about high dose chemotherapy(HDT)...I think it is a misnomer to call it a SCT as that is not the therapy but rather the salvage after they scorch the marrow beyond it being life sustaining. So many patients think they are getting a 'transplant' if it is autologous they are NOT. The HDT is the therapy. Which is the reason, I am not an 'upfront' SCT proponent, not to mention that 50% of autologous SCT are failures. So what you are betting on is the HDT..and since they have been doing that for 30 years..and you hear incurable right after multiple myeloma diagnosis..I am extremely hesitant to make that choice. Younger patients and those without cytogenetic abnormalities seem to do best with that choice...I am neither category.
Stick to your guns and know the outcomes for your choices as well as the risks vs. benefits..and that is all any of us can do. Bottom line it comes down to personal choices.
Wishing you good choices!!
suzierose
I think you will be pleased with Jakubowiak...he is a good buddy of Langren.so I think that bodes well.
I hear you about high dose chemotherapy(HDT)...I think it is a misnomer to call it a SCT as that is not the therapy but rather the salvage after they scorch the marrow beyond it being life sustaining. So many patients think they are getting a 'transplant' if it is autologous they are NOT. The HDT is the therapy. Which is the reason, I am not an 'upfront' SCT proponent, not to mention that 50% of autologous SCT are failures. So what you are betting on is the HDT..and since they have been doing that for 30 years..and you hear incurable right after multiple myeloma diagnosis..I am extremely hesitant to make that choice. Younger patients and those without cytogenetic abnormalities seem to do best with that choice...I am neither category.
Stick to your guns and know the outcomes for your choices as well as the risks vs. benefits..and that is all any of us can do. Bottom line it comes down to personal choices.
Wishing you good choices!!
suzierose
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Thanks suzirose
I did talk with Dr Landgren about Dr J. and he has nothing but good things to say. Also have talked to some here on the Beacon. Looking forward to seeing him. I'll keep you posted.
I agree and absolutely I am very aware of the outcomes and the risk v. benifits.
Thanks Again
Art
I did talk with Dr Landgren about Dr J. and he has nothing but good things to say. Also have talked to some here on the Beacon. Looking forward to seeing him. I'll keep you posted.
I agree and absolutely I am very aware of the outcomes and the risk v. benifits.
Thanks Again
Art
-
Art - Name: Art
- Who do you know with myeloma?: Self
- When were you/they diagnosed?: 12/2011
- Age at diagnosis: 40
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Art,
I am sure Dr. Jakubowiak would want you to stay on Myeloma therapy for a long time - it would definitely be good for him financially. Check out his Disclosure statement from his 2011 ASH papers.
"Jakubowiak: Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Onyx Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Ortho Biotech: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Exelixis: Consultancy, Honoraria."
https://ash.confex.com/ash/2011/webprogram/Paper37860.html
Mark
I am sure Dr. Jakubowiak would want you to stay on Myeloma therapy for a long time - it would definitely be good for him financially. Check out his Disclosure statement from his 2011 ASH papers.
"Jakubowiak: Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Onyx Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Ortho Biotech: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Exelixis: Consultancy, Honoraria."
https://ash.confex.com/ash/2011/webprogram/Paper37860.html
Mark
-
Mark
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Hi, my husband was newly diagnosed a year ago with multiple myeloma and began the Carfilzomib/Revlimid/Dex therapy starting in June 2011. He is in a clinical study at the Univ of Michigan, where Dr. Jakubiak previously headed the multiple myeloma research before going to Chicago. We never met him, but he has the most wonderful assistant, Anne, who coordinated our entry into the U-M multiple myeloma program. We were so sad to learn she was also going to Chicago!
The C/R/D study protocol calls for treatment to continue another 12 months (total of 24 mos) and then he will be on Revlimid maintenance therapy. He did have his stem cells collected between cycles 4 and 5 in case he needs that in the future-- hopefully not.
My husband's M-protein has dropped from 4.9 to 0.1, where it has plateaued now for several months (4 or more, I think). He has still unfortunately experienced many multiple myeloma "textbook " complications (infections, broken rib, difficulty breathing, DVT, fatigue, muscle cramps, and Dex issues.) Despite not achieving complete response, we've been told that even in cycle 23 or 24 there could still be a reduction in M protein. And, we're very thankful that he doesn't have the neuropathy from Carfilzomib to the extent other treatments can cause.
Carfilzomib seems to be a good weapon to have in battle against multiple myeloma, and I hope it can eventually beat his multiple myeloma the rest of the way to CR. And I hope the FDA will approve it next month beyond just the use in studies.
The C/R/D study protocol calls for treatment to continue another 12 months (total of 24 mos) and then he will be on Revlimid maintenance therapy. He did have his stem cells collected between cycles 4 and 5 in case he needs that in the future-- hopefully not.
My husband's M-protein has dropped from 4.9 to 0.1, where it has plateaued now for several months (4 or more, I think). He has still unfortunately experienced many multiple myeloma "textbook " complications (infections, broken rib, difficulty breathing, DVT, fatigue, muscle cramps, and Dex issues.) Despite not achieving complete response, we've been told that even in cycle 23 or 24 there could still be a reduction in M protein. And, we're very thankful that he doesn't have the neuropathy from Carfilzomib to the extent other treatments can cause.
Carfilzomib seems to be a good weapon to have in battle against multiple myeloma, and I hope it can eventually beat his multiple myeloma the rest of the way to CR. And I hope the FDA will approve it next month beyond just the use in studies.
-
Chris
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Hi Chris,
I am also in the trial at UofM, and was also sorry to see both Dr. J and Anne leave for the University of Chicago. Don't know if your husband sees Kristin or Terra, but I usually meet with Kristin and think she's phenomenal. With respect to CR, I was at M-Spike of 0.1 for seven months until I finally reached CR/sCR after my 11th cycle, so your husband may still reach it - sure hope he does. If you ever see me at the hospital, please introduce yourself since it's always nice to get to know others that are part of the program (note, I no longer have a beard now that the warm weather is here).
I am also in the trial at UofM, and was also sorry to see both Dr. J and Anne leave for the University of Chicago. Don't know if your husband sees Kristin or Terra, but I usually meet with Kristin and think she's phenomenal. With respect to CR, I was at M-Spike of 0.1 for seven months until I finally reached CR/sCR after my 11th cycle, so your husband may still reach it - sure hope he does. If you ever see me at the hospital, please introduce yourself since it's always nice to get to know others that are part of the program (note, I no longer have a beard now that the warm weather is here).
-
Kevin J - Name: Kevin J
- Who do you know with myeloma?: myself
- When were you/they diagnosed?: Jan 2011
- Age at diagnosis: 52
Re: ASCO 2012 carfilzomib/Len/Dex..Jakubowiak
Hi Kevin,
My husband was very interested to hear your M- protein had plateaued, too, before getting to CR. We wish you all the best and if we happen to see you down at U-M in the future, we will definitely say Hi!
My husband was very interested to hear your M- protein had plateaued, too, before getting to CR. We wish you all the best and if we happen to see you down at U-M in the future, we will definitely say Hi!
-
Chris
10 posts
• Page 1 of 1
Return to Treatments & Side Effects